Västra Hamnen Corporate Finance initiates Research Coverage on Scandinavian ChemoTech
Scandinavian ChemoTech AB (publ) and Västra Hamnen Corporate Finance AB (VH) have signed a contract to perform commissioned equity research.
In its initial research report, VH writes the following:
”ChemoTech is a young medical technology company in the first stage of commercialising its innovative equipment for cancer treatment. The company has redeveloped electrochemotherapy, a proven method for tumour treatment, and created a solution which is both effective and much cheaper than competing methods. ChemoTech may thereby bring much needed treatment to cancer patients in the developing world, many of whom would otherwise have no access to treatment”
…
“We have estimated fair value for the company using two different approaches, a DCF model and a peer valuation. The DCF model suggests a fair value range for the stock price from SEK 18.20 to SEK 26.70. This valuation excludes the two development projects and all geographic markets outside the current scope, as we find them too hard to quantify at present. Our peer valuation points to a fair value range between SEK 26.30 and SEK 58.40.”
The complete research report is to be found here.
For more information, please contact:
Mohan Frick, CEO
+46 (0)10-218 93 00
Scandinavian ChemoTech AB (publ)
ChemoTech is a young and dynamic life science company that possesses a great medical expertise and technical knowledge. Our latest launch of IQwave™ is an innovation within electrochemotherapy, that is adapted for the treatment of different types of tumors. ChemoTech strives to contribute to a more accessible cancer care. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North in Stockholm and Västra Hamnen Corporate Finance AB is the company's Certified Adviser. The company is headquartered in Malmö, in the midst of the medical technology expansionary Öresund region.